MCF-7 cells are grown in 5 mL of RPMI 1640 medium supplemented with 20% fetal bovine serum, penicillin (100 U/mL) and streptomycin (100 μg/mL). Cells are maintained at 37°C in a humidified atmosphere of 5% CO₂ in air and subcultured every 3 days. Exponentially growing cells are plated at a seeding density of 2×10⁴ cells/mL, in 96-well plates or in dishes. After overnight incubation to allow for attachment, the cells are exposed for 24 or 48 h to various concentrations of Procyanidin B2 (0.5; 1.0; 5.0; 10.0; 25.0 and 50.0 μM) diluted in distilled water. Two millimolar cyclophosphamide (CP) is used as the positive control and solutions are sterilised by filtration^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

To observe the effect of Procyanidin B2 on infarct size or brain edema, 40 rats are randomLy separated into five groups, and each group is administered with vehicle (equivalent dose of 0.9% saline administered via gavage) or 40, 20, or 10 mg/kg of Procyanidin B2, respectively. To elucidate the effect of Procyanidin B2 on blood-brain barrier (BBB) permeability, the rats (n = 6 per group for Evans blue extravasation and n = 4 per group for IgG leakage) are randomLy separated into two groups: vehicle and Procyanidin B2 (40 mg/kg). Procyanidin B2 (40 mg/kg) is administered intragastrically once a day starting at 3 h after middle cerebral artery occlusion (MCAO). For other observations, including immunohistological staining and western blot analysis, rats are randomLy separated into three groups: sham-operated, vehicle, and Procyanidin B2 (n = 4 per group). Procyanidin B2 (40 mg/kg) is administered intragastrically once a day starting at 3 h after MCAO. To elucidate the improvement in neurological function after ischemic stroke in rats, the rats (n = 8 per group) undergo neurobehavioral assays to evaluate the functional outcome after administration of Procyanidin B2 (40 mg/kg) once a day starting at 24 h after MCAO. The neurological deficits are assessed at 1, 3, 7, 11, and 14 days after MCAO^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

• [1]. Avelar MM, et al. Procyanidin b2 cytotoxicity to mcf-7 human breast adenocarcinoma cells. Indian J Pharm Sci. 2012 Jul;74(4):351-5.

  [2]. Yang H, et al. Procyanidin B2 inhibits NLRP3 inflammasome activation in human vascular endothelial cells. Biochem Pharmacol. 2014 Dec 15;92(4):599-606.

  [3]. Wu S, et al. Procyanidin B2 attenuates neurological deficits and blood-brain barrier disruption in a rat model of cerebral ischemia. Mol Nutr Food Res. 2015 Oct;59(10):1930-41.

578.52

C₃₀H₂₆O₁₂

29106-49-8

O[C@H]1[C@@H](C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3[C@@H]1C4=C5C(C[C@@H](O)[C@@H](C6=CC=C(O)C(O)=C6)O5)=C(O)C=C4O

Room temperature in continental US; may vary elsewhere